| Title: |
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium |
| Authors: |
Han, JX; Koh, MJ; Boussi, L; Sorial, M; McCabe, SM; Peng, L; Singh, S; Eche-Ugwu, IJ; Gabler, J; Fernandez Turizo, MJ; MacVicar, CT; Garg, A; Disciullo, A; Chopra, K; Lenart, A; Nwodo, E; Barnes, J; Miranda, E; Chiattone, C; Stuver, R; Horwitz, SM; Merrill, M; Jacobsen, E; Manni, M; Civallero, M; Skrypets, T; Lymboussaki, A; Federico, M; Kim, Y; Kim, JS; Cho, JY; Eipe, T; Shet, T; Sridhar, E; Shetty, A; Saha, S; Jain, H; Sengar, M; Van Der Weyden, C; Prince, HM; Hamouche, R; Murdashvili, T; Foss, F; Gentilini, M; Casadei, B; Zinzani, PL; Okatani, T; Yoshida, N; Yoon, SE; Kim, WS; Panchoo, G; Mohamed, Z; Verburgh, E; Alturas, JC; Al-Mansour, M; Ford, J; Cabrera, ME; Ku, A; Bhagat, G; Ma, H; Sawas, A; Kariya, KM; Iwasaki, M; Bhanushali, F; O’Connor, OA; Marchi, E; Shen, C; Shah, D; Jain, S |
| Publisher Information: |
American Society of Hematology |
| Publication Year: |
2025 |
| Collection: |
The University of Melbourne: Digital Repository |
| Description: |
Variances in global access to drugs and treatment practices make it challenging to understand the benefit of contemporary therapies in patients with relapsed and refractory (R/R) mature T-cell and natural killer-cell lymphomas (MTCL and MNKCL). We conducted an international retrospective cohort study of 925 patients with R/R MTCL and MNKCL. In peripheral T-cell lymphoma-not otherwise specified and anaplastic lymphoma kinase-negative anaplastic large cell lymphoma (ALK- ALCL), patients with relapsed lymphoma demonstrated a superior median overall survival (OS) relative to refractory from the time of second-line treatment. We identified several independent predictors of OS for R/R lymphoma including age >60 years, primary refractory disease, histological subtype other than angioimmunoblastic T-cell lymphoma (AITL), extranodal sites >1, Ki67 ≥40%, and absolute lymphocyte count less than the lower limit of normal. A multivariable model incorporating these formed the basis for a prognostic index for R/R TCL, in which patients are stratified into low-risk (0-1 risk factor), intermediate-risk (2-3 risk factors), or high-risk (≥4 risk factors) groups, which were associated with 3-year OS of 57.14%, 23.3%, and 7%, respectively. Patients received either a "novel" single agent (SA; 35%) or cytotoxic chemotherapy (CC; 60%) for their second-line treatment. Higher progression-free survival was observed with SA over CC for the entire cohort with a higher 3-year OS in AITL and ALK- ALCL. Among the SA, small-molecule inhibitors demonstrated OS advantage relative to CC in AITL. Our results highlight continued efficacy of novel drugs globally and the potential of a new prediction model in informing heterogeneous prognosis within the R/R population of MTCL and MNKCL. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| ISSN: |
2473-9529 |
| Relation: |
pii: 525844; https://hdl.handle.net/11343/359081 |
| Availability: |
https://hdl.handle.net/11343/359081 |
| Rights: |
https://creativecommons.org/licenses/by-nc-nd/4.0 ; CC BY-NC-ND |
| Accession Number: |
edsbas.AF0AAE88 |
| Database: |
BASE |